SAGE - SAGE Therapeutics Inc. (SAGE) Q4 2023 Earnings Call Transcript

2024-02-14 13:00:04 ET

SAGE Therapeutics, Inc. (SAGE)

Q4 2023 Earnings Conference Call

February 14, 2024, 8:00 a.m. ET

Company Participants

Barry Greene - President, CEO & Director

Kimi Iguchi - CFO & Treasurer

Laura Gault - Chief Medical Officer

Chris Benecchi - Chief Business Officer

Ashley Kaplowitz - Director, IR

Conference Call Participants

Matt Leskowitz - Goldman Sachs

Anupam Rama - J.P. Morgan

Ritu Baral - TD Cowen

James Condulis - Stifel

Tazeen Ahmad - Bank of America

Brian Abraham - RBC Capital Markets

Poorna Kannan - Needham & Company

Laura Chico - Wedbush Securities

Neena Bitritto-Garg - Deutsche Bank

George Farmer - Scotiabank

Sumant Kulkarni - Canaccord Genuity

Phoebe Tan - Jefferies

Yatin Sunej - Guggenheim

Vikram Purohit - Morgan Stanley

Marc Goodman - Leerink Partners

Presentation

Operator

Good morning. Welcome to SAGE Therapeutics' Fourth Quarter and Full Year 2023 Financial Results Conference Call. [Operator Instructions]. This call is being webcast live on the Investors and Media section of SAGE’s website at SAGErx.com. This call is the property of SAGE Therapeutics and recording, reproduction or transmission of this call without the express written consent of SAGE Therapeutics, is strictly prohibited. Please note that this call is being recorded.

I would now like to introduce Ashley Kaplowitz, Executive Director of Investor Relations and Capital Markets at SAGE.

Ashley Kaplowitz

Good morning, and thank you for joining SAGE Therapeutics' Fourth Quarter and Full-Year 2023 Financial Results Conference Call. Before we begin, I encourage everyone to go to the Investors and Media section of our website at SAGErx.com where you can find the press release and slides related to today’s call.

I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and our actual results may differ materially. Please review the risk factors discussed in today's press release and in our SEC filings for additional details....

For further details see: